Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0696 • ACR Convergence 2021
Anti-Transcriptional Intermediary Factor 1-gamma Antibodies in Dermatomyositis with and Without Cancer – A Longitudinal Study
Lara Dani¹, Sandra Selickaja², Angeles Shunashy Galindo-Feria³, John Svensson⁴, Paulius Venalis⁵, Dag Leonard⁶, Malin Hemberg⁷, Balsam Hanna⁸, Ingrid E Lundberg⁹ and Marie Holmqvist⁴, ¹Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²State Research Institute for Innovative Medicine and Vilnius university hospital Santaros Klinikos, Vilnius, Lithuania, ³Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Department of Rheumatology, Uppsala University, Uppsala, Sweden, ⁷Rheumatology Unit, Falu Lasarett, Falun, Sweden, ⁸Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁹Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: To longitudinally follow the levels of anti- transcriptional intermediary factor (TIF)1-gamma autoantibodies in patients with dermatomyositis with and without cancer.Methods: We identified sera from…
Abstract Number: 1377 • ACR Convergence 2021
Assessment of Autoantibodies and Clinical Associations in SSc Patients with ANA Positivity & Negative for Prototypic Autoantibodies
Karen Kruzer¹, Roberta G Marangoni¹, Ilana Heckler², Aya Elhage², Varga John³, Monique Hinchcliff⁴, Mary Carns⁵, Kathleen Aren⁵, Amy Wielgosz¹, Marc Nuzzo⁶, Iswariya Venkataraman² and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²EUROIMMUN US, Mountain Lakes, NJ, ³University of Michigan, Ann Arbor, MI, ⁴Yale School of Medicine, Westport, CT, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic sclerosis (SSc) is a clinically heterogenous disease typically characterized by a positive ANA (ANA+), and prototypical antibodies including anti-centromere, anti-topoisomerase, and anti-RNA polymerase…
Abstract Number: 1535 • ACR Convergence 2021
Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination
Rebecca Blank¹, Rebecca Haberman², Rochelle Castillo², marie Samanovic³, Parvathy Vasudevanpillai Girija⁴, Paula Rackoff¹, Gary Solomon⁵, Natalie Azar⁶, Pamela Rosenthal⁷, Peter Izmirly⁴, Jonathan Samuels⁸, Brian Golden⁹, Soumya Reddy⁷, Steven B. Abramson⁴, Mark Mulligan³ and Jose Scher⁴, ¹New York University, New York, NY, ²NYU Langone Health, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU Langone School of Medicine, Hartsdale, NY, ⁶NYU Langone, New York, NY, ⁷NYU School of Medicine, New York, NY, ⁸NYU Langone, Rye Brook, NY, ⁹NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Recent studies have shown high rates of autoantibody production in patients hospitalized with COVID-19, including antinuclear antibodies (ANA) and antibodies associated with antiphospholipid syndrome.…
Abstract Number: 0012 • ACR Convergence 2021
A Novel Mechanism Linking Mucosal Bacteria with Autoantibody Responses in RA: Acetylated Bacterial Lysate as a Model Antigen
Mikhail Volkov, Arieke Kampstra, Karin van Schie, Joanneke Kwekkeboom, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies against post-translationally modified proteins (AMPA) such as citrullinated, carbamylated and acetylated proteins. Importantly, these antibodies are highly…
Abstract Number: 0181 • ACR Convergence 2021
Magnetic Resonance Imaging Findings in Early Rheumatoid Arthritis: Are There Differences Based on Autoantibody Status?
Caitrin Coffey¹, Gavin McKenzie¹, Nicholas Rhodes¹, Cassondra Hulshizer¹, Cynthia Crowson², John Davis¹ and Kerry Wright¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Magnetic resonance imaging (MRI) is increasingly used as an adjunct to the physical examination in early rheumatoid arthritis (RA). Characteristic differences in MRI findings…
Abstract Number: 0697 • ACR Convergence 2021
Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
Angeles Shunashy Galindo-Feria¹, Begum Horuluoglu¹, Jessica Day², Catia Cerqueira³, Edvard Wigren⁴, Susanne Gräslund⁴, Susanna Proudman⁵, Ingrid E Lundberg⁴ and Vidya Limaye⁶, ¹Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ³4Dcell, Montreuil, France, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵University of Adelaide, Medindie, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), have been previously identified in patients with idiopathic inflammatory myopathies (IIM) (1). The aim of this…
Abstract Number: 1378 • ACR Convergence 2021
Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort
Matthew Kirkpatrick¹, Janet Lee¹, Anne Tebo², Haojia Li¹, yue zhang¹ and Tracy Frech¹, ¹University of Utah, Salt Lake City, UT, ²Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Autoantibodies are included in the disease classification criteria for systemic sclerosis (SSc). Our group previously reported the level of topoisomerase autoantibody as an important…
Abstract Number: 1551 • ACR Convergence 2021
Generation of Autoantibodies and Their Association with Rheumatic Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Adult Population Following BNT162b2 mRNA Covid-19 Vaccination
Tal Gazitt¹, Joy Feld², Amir Haddad³, Muna Elias⁴, Nizar Hijazi⁴, Nili Stein⁴, Victoria Furer⁵, Tali Eviatar⁶, Hagit Peleg⁷, Ori Elkayam⁸ and Devy Zisman⁴, ¹Carmel Hospital, Haifa, Israel, ²Carmel and Zvulun Medical Centre, Haifa, Israel, ³Carmel Medical Centre, Haifa, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Tel Aviv Sourasky Medical Center, Givataim, Israel, ⁷Hadassah Medical Center, Jerusalem, Israel, ⁸Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The rapid spread of the COVID-19 pandemic has created the need for mass vaccination of patients with autoimmune rheumatic disease (AIIRD) despite the lack…
Abstract Number: 0015 • ACR Convergence 2021
Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules
Shanshan Zhang¹, Hideaki Tsuji¹, Hui Jin², Koji Kitagori¹, Shuji Akizuki³, Kosaku Murakami¹, Ran Nakashima¹, Hajime Yoshifuji¹, Masao Tanaka¹, Hisashi Arase², Koichiro Ohmura⁴ and Akio Morinobu¹, ¹Kyoto University, Kyoto, Japan, ²Osaka University, Osaka, Japan, ³Kyoto Universtiy, Kyoto City, Japan, ⁴Kobe City Medical Center General Hospital, Kobe, Japan
Background/Purpose: Rheumatoid factor (RF) is an autoantibody that binds to IgG Fc region (CH2 and CH3 domains) and is detectable in patients with rheumatoid arthritis…
Abstract Number: 0269 • ACR Convergence 2021
Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans with Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee², Carlos Hunter², Punyasha Roul², Yangyuna Yang², Jeremy Sokolove³, William Robinson⁴, Joshua Baker⁵, Geoffrey Thiele², Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Stanford University School of Medicine, Berwyn, PA, ⁴Stanford University, Stanford, CA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Autoantibodies are hypothesized as one of the RA specific factors contributing to a heightened risk of cardiovascular disease (CVD) in this population. However, prior…
Abstract Number: 0702 • ACR Convergence 2021
Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing
Sarvar Nazir¹, Lisa Rider², Ira Targoff³, Stanley Naides⁴, Andrew Mammen⁵, Steven Greenberg⁶ and Adam Schiffenbauer⁵, ¹NIEHS, NIH, Bethesda, MD, ²NIEHS, NIH, Garrett Park, MD, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Self, Dana Point, CA, ⁵National Institutes of Health, Bethesda, MD, ⁶Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions. The presence of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) in patients…
Abstract Number: 1423 • ACR Convergence 2021
Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
Melissa Munroe¹, Rufei Lu², Timothy Gross¹, George Tsokos³, Michael Keith⁴, John Harley⁵ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, OUHSC, Oklahoma City, OK, ³BIDMC, Boston, MA, ⁴Inova, Arlington, VA, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: SLE is a chronic autoimmune disease driven by immune dysregulation. We have previously identified patterns of disordered immunity present prior to and concurrent with…
Abstract Number: 1841 • ACR Convergence 2021
Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases
Louisa-Marie Mockenhaupt¹, Ramona Dolscheid-Pommerich¹, Charlotte Behning¹, Birgit Stoffel-Wagner², Peter Brossart¹ and Valentin Schäfer¹, ¹University Hospital Bonn, Bonn, Germany, ²University Hospital Bonn, Bonn
Background/Purpose: Antinuclear antibodies (ANA) are serological markers for the presence of connective tissue diseases [1]. In some patients, a pattern can be detected in ANA…
Abstract Number: 0017 • ACR Convergence 2021
Lessons Learnt from Associations Between Anti-modified Protein Antibodies and Risk Factors: Human Leukocyte Antigen – Shared Epitope Alleles Solely Associate with Anti-citrullinated Protein Antibodies
Tineke J van wesemael, Annemarie L. Dorjee, Tom WJ Huizinga, Annette H.M van der Helm-van Mil, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of auto-antibodies to post translationally modified proteins (anti-modified protein antibodies (AMPA)): anti-citrullinated protein antibodies (ACPA), anti-carbamylated…
Abstract Number: 0288 • ACR Convergence 2021
Demographic, Lifestyle, and Clinical Risk Factors for Rheumatoid Arthritis-Associated Bronchiectasis: Role of RA-related Autoantibodies
Gregory McDermott¹, Ritu Gill², Staci Gagne³, Suzanne Byrne³, Weixing Huang³, Lauren Prisco⁴, Alessandra Zaccardelli³, Lily Martin³, Nancy Shadick⁵, Paul Dellaripa³, Tracy Doyle⁶ and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Pound Ridge, MA, ⁵Brigham & Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Bronchiectasis is a known extra-articular manifestation of rheumatoid arthritis (RA) characterized by bronchial damage and excessive mucus production that predispose patients to risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].